CAMBRIDGE, Mass., October 07, 2022--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. ("Amylyx") today announced the pricing of an upsized underwritten public offering of 6,693,750 shares of its common stock at a public offering price of $32.00 per share.
All of the shares of common stock are being offered by Amylyx. Amylyx has granted the underwriters a 30-day option to purchase up to an additional 1,004,062 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Amylyx from this offering are expected to be $214.2 million, before deducting underwriting discounts and commissions and offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about October 11, 2022, subject to the satisfaction of customary closing conditions.
Goldman Sachs & Co. LLC, BofA Securities, SVB Securities, and Evercore ISI are acting as joint book-running managers for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering.
Registration statements on Form S-1 relating to these securities became effective on October 6, 2022. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering, may be obtained, when available, from: Goldman Sachs & Co. LLC, at Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526 or by e-mail at prospectus-ny@ny.email.gs.com; BofA Securities, Inc., Attention: Prospectus Department, 200 North College Street, 3rd floor, Charlotte NC 28255-0001 or by email at dg.prospectus_requests@bofa.com; SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525, ext. 6105, or by email at syndicate@svbsecurities.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at 1-888-474-0200, or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada and EMEA.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements", including with respect to the offering. No assurance can be given that the offering discussed above will be completed. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Any forward-looking statements in this statement are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include those risks and uncertainties set forth in Amylyx’ registration statement on Form S-1 filed with the United States Securities and Exchange Commission and the preliminary prospectus included therein. Copies of the registration statement can be accessed by visiting the Securities and Exchange Commission website at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221006006078/en/
Becky Gohsler Finn Partners (646) 307-6307 amylyxmediateam@amylyx.com
Lindsey Allen Amylyx Pharmaceuticals, Inc. (857) 320-6244 Investors@amylyx.com
By buying an index fund, investors can approximate the average market return. But many of us dare to dream of bigger...
Contrary to popular belief, the simple approach to many things in life is often the most effective. An investing quote from Motley Fool contributor Brian Feroldi that I believe is highly underrated goes as follows: "Good investing is 99% patience and 1% action." The pharmaceutical giant Amgen (NASDAQ: AMGN) and medical devices maker Stryker (NYSE: SYK) are two healthcare stocks that appear poised to create wealth for shareholders who are patient and measured enough to let them.
The fact that multiple Amgen Inc. ( NASDAQ:AMGN ) insiders offloaded a considerable amount of shares over the past year...
It may not be practical — at least for now.
Take a look at this list of stock market holidays in 2022 to find out whether the market will be open on days like Labor Day, Black Friday, Christmas Eve and more.
The market rally attempt is reeling, back near bear lows. What will investors discover on Columbus Day?
Oil prices have bounced around quite a bit this year. Brent oil, the global-pricing benchmark, started 2022 below $80 a barrel before soaring into the $120s following Russia's invasion of Ukraine. With the prospect of higher oil prices, we asked some of our energy contributors what oil stocks they believe are best positioned to capitalize following OPEC's bold move.
Each month I buy several dividend stocks to help build my passive income stream toward my goal of having it eventually offset my expenses. This October, I plan to add to my positions in Blackstone Group (NYSE: BX), Clearway Energy (NYSE: CWEN)(NYSE: CWEN.A), Digital Realty (NYSE: DLR), Realty Income (NYSE: O), and NextEra Energy (NYSE: NEE) as more cash flows into my portfolio.
The S&P 500 market index is down more than 30% year to date and the more growth-oriented Nasdaq Composite lost more than 30% over the same span. Taken together, these two effects make me want to pound the table about investing in Intel (NASDAQ: INTC) and International Business Machines (NYSE: IBM) right now. Semiconductor giant Intel's latest earnings report was admittedly disappointing.
Intel (NASDAQ: INTC) has been under tremendous pressure this year. Shares of the semiconductor company have tumbled about 50%. While Intel is facing its share of headwinds, I believe better days lie ahead for the tech giant and its big-time dividend.
These companies have the fuel to continue piping income into their investors' pockets in the coming years.
Alphabet Inc.'s ( NASDAQ:GOOGL ) price-to-earnings (or "P/E") ratio of 17.9x might make it look like a sell right now...
You would think this would be TIPS’ time to shine. Instead, the prices of Treasury inflation-protected securities—government bonds that are adjusted to keep up with inflation—have declined this year, even as inflation has soared. The comparable loss for ICE’s index of regular Treasury bonds was 13.5%.
The three stocks that stood out to me are Taiwan Semiconductor (NYSE: TSM), Disney (NYSE: DIS), and Adobe (NASDAQ: ADBE). The company is a third-party manufacturer for chip leaders like Apple (NASDAQ: AAPL), Nvidia (NASDAQ: NVDA), and dozens of other companies designing their own chips.
The Federal Open Market Committee will release the minutes from its September meeting on Wednesday, and the Bureau of Labor Statistics will report the September consumer price index on Thursday morning.
The company's longtime CEO announced his retirement, leading some analysts to contemplate a cut to the 14% dividend.
To those who have never experienced a run-of-the-mill recession, everything looks like a crisis. That could mean bank stocks are due for a run-up.
The company is reaping benefits from investments in 5G technology, but that's not necessarily enough to make AT&T stock a buy.
Investors are betting heavily on a decline in stock prices. They're usually right, according to research.
(Bloomberg) -- The conventional wisdom with stock bulls is that prices will take off when the Federal Reserve wins its fight against inflation. But the end of surging consumer costs could unleash another round of bad news.Most Read from BloombergRussia Races to Reopen Crimea Bridge Damaged in Fiery BlastUkraine Latest: Putin Calls Security Meeting, Comments on BridgePutin Orders Sakhalin-1 Project Transferred to Russian EntityEight Years of Combat Hardened Ukraine’s Army Into a Fighting ForceA s